{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:55:20Z","timestamp":1792688120818,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaad.2022.11.043","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T02:20:38Z","timestamp":1669774838000},"page":"534-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors"],"prefix":"10.1016","volume":"88","author":[{"given":"Margaret Ann","family":"Kreher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh","family":"Konda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Margaret B.","family":"Noland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Valdes-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2022.11.043_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.11.043_bib2","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.043_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study","volume":"55","author":"Lange","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.043_bib5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jaad.2022.11.043_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.043_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.043_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2022.11.043_bib9","series-title":"StatPearls","article-title":"Tumor necrosis factor inhibitors","author":"Gerriets","year":"2022"},{"key":"10.1016\/j.jaad.2022.11.043_bib10","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.043_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.043_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van L\u00fcmig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2022.11.043_bib13","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.043_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CMR.0000000000000284","article-title":"Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jaad.2022.11.043_bib16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries\u00a0and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.043_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.11.043_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.043_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.043_bib21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.043_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.043_bib24","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.043_bib25","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13311-021-01073-y","article-title":"Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: a WHO pharmacovigilance database analysis","volume":"18","author":"Dolladille","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.jaad.2022.11.043_bib26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.043_bib27","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.043_bib28","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1111\/ctr.12094","article-title":"Cancer risk with alemtuzumab following kidney transplantation","volume":"27","author":"Puttarajappa","year":"2013","journal-title":"Clin Transpl"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib29","first-page":"561","article-title":"Ibrutinib presents antitumor activity in skin cancer and induces autophagy","volume":"22","author":"Sun","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaad.2022.11.043_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2021.10.034","article-title":"Ibrutinib-related skin cancer: a pharmacovigilance study from the Food and Drug Administration adverse event reporting system","volume":"160","author":"Sun","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.043_bib31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2022.11.043_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.043_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","article-title":"Janus kinase inhibitors and non-melanoma skin cancer","volume":"22","author":"Greif","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.043_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jaad.2022.11.043_bib37","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","article-title":"Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies","volume":"100","author":"Sekhri","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.043_bib38","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.11.043_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dth.12046","article-title":"Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris","volume":"27","author":"Wilsmann-Theis","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2022.11.043_bib40","doi-asserted-by":"crossref","first-page":"696597","DOI":"10.3389\/fmed.2021.696597","article-title":"Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease","volume":"8","author":"Arora","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222031462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222031462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:08:29Z","timestamp":1759273709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222031462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0190962222031462"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.044","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}